Trial · NCT03738618
Outcomes69
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 69
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of Controlled Ovarian Stimulation (COS) | 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | percentage of participants | NUMBER |
| SECONDARY | Ongoing Pregnancy Rate in the Fresh Cycle and in the Cryopreserved Cycles | 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | percentage of participants | NUMBER |
| SECONDARY | Time From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Including Duration | 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | days | MEAN |
| SECONDARY | Time From Start of COS to Ongoing Pregnancy Across the Fresh and Cryopreserved Cycles, Measured in Number of Cycles Before Achieving Ongoing Pregnancy | 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | Cycles | MEAN |
| SECONDARY | Ongoing Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively | 8-9 weeks after transfer (up to approximately 16 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | % of viable fetus/blastocyst transfer | NUMBER |
| SECONDARY | Clinical Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively | 5-6 weeks after transfer (up to approximately 15 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | percentage of participants | NUMBER |
| SECONDARY | Vital Pregnancy Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively | 5-6 weeks after transfer (up to approximately 15 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | percentage of participants | NUMBER |
| SECONDARY | Implantation Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively | 5-6 weeks after transfer (up to approximately 15 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | % gestational sacs/blastocyst transfer | NUMBER |
| SECONDARY | Positive Beta Human Chorionic Gonadotropin (βhCG) Rate in the Fresh Cycle, the Cryopreserved Cycles and Cumulatively | 10-14 days after transfer (up to approximately 14 months after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | percentage of participants | NUMBER |
| SECONDARY | Proportion of Subjects in the Fresh Cycle With Triggering of Final Follicular Maturation (With hCG, With GnRH Agonist, and in Total), Cycle Cancellation and Transfer Cancellation | Up to 5 days after oocyte retrieval (up to 27 days after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | percentage of participants | NUMBER |
| SECONDARY | Number of Follicles on Stimulation Day 5 | On stimulation day 5 | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | number of follicles | MEAN |
| SECONDARY | Number of Follicles at End-of-stimulation | At end-of-stimulation (up to 20 stimulation days) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | number of follicles | MEAN |
| SECONDARY | Size of Follicles on Stimulation Day 5 | On stimulation day 5 | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | mm | MEAN |
| SECONDARY | Size of Follicles at End-of-stimulation | At end-of-stimulation (up to 20 stimulation days) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | mm | MEAN |
| SECONDARY | Number of Oocytes Retrieved | On day of oocyte retrieval (up to 22 days after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | number of oocytes retrieved | MEAN |
| SECONDARY | Proportion of Subjects With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved | On day of oocyte retrieval (up to 22 days after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | percentage of participants | NUMBER |
| SECONDARY | Number of Metaphase II Oocytes | On day of oocyte retrieval (up to 22 days after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | number of MII oocytes | MEAN |
| SECONDARY | Number of Fertilized Oocytes | On day 1 after oocyte retrieval (up to 23 days after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | oocytes (number of fertilized oocytes) | MEAN |
| SECONDARY | Fertilization Rate | On day 1 after oocyte retrieval (up to 23 days after start of stimulation) | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | percentage of fertilized oocytes | MEAN |
| SECONDARY | Number and Quality of Blastocysts on Day 5 After Oocyte Retrieval | On day 5 after oocyte retrieval | The mITT analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment. | blastocysts | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03738618/outcomes